Chief Executive Officer
Mr. Labinger has nearly three decades of pharmaceutical and biotech industry experience, with leading roles at Emergent BioSolutions, Human Genome Sciences, 3M Pharmaceuticals, and Immunex. He most recently served as Executive Vice President and President, Biosciences Division, at Emergent BioSolutions Inc., where he was responsible for all aspects of product development, manufacturing, and commercialization, including the advancement of partnering initiatives. Mr. Labinger has an MBA from J.L. Kellogg Graduate School of Management at Northwestern University and BA in economics, also from Northwestern University.
Bruno Osterwalder, MD
Chief Medical Advisor
Dr. Osterwalder advises Biothera Pharmaceuticals on clinical development, medical affairs, and other functions related to the advancement of Imprime PGG. He is a former Senior Vice President, Senior Strategic Advisor Oncology and Head of Early Oncology, Global Research and Drug Development for Merck Serono. Previously, Dr. Osterwalder held various positions with increasing responsibilities in global drug development at F. Hoffmann-Roche, with a focus on novel drugs in hematology, oncology and renal and cancer anemia. He has 15 years academic/clinical practice in internal medicine, hematology and oncology (Swiss board certifications). Dr. Osterwalder received a medical degree from the University of Zurich and is board-certified in hematology and oncology.
Jeremy R. Graff, PhD
Chief Scientific Officer
Senior Vice President, Research
Dr. Graff joined Biothera in late 2014 to lead research efforts to refine the Company’s understanding of the anti-cancer therapeutic activity of Imprime PGG, and to provide the foundation for biomarker-driven patient selection strategies. Before joining Biothera, he was a Research Fellow and Group Leader – Oncology Patient Tailoring at Eli Lilly and Company in Indianapolis. Dr. Graff completed his post-doctoral fellowship 1998 at Johns Hopkins University Medical School, establishing that metastasis suppressor genes could be epigenetically inactivated in human cancers. He received his Ph.D. from the University of Kentucky, studying oncogenic ras signaling and metastasis. He serves on the editorial board for Cancer Research, the flagship journal for the American Association of Cancer Research. He has also served on numerous grant review panels for the American Cancer Society, the Department of Defense and Genome Quebec. He has published more than 50 peer-reviewed manuscripts that have collectively garnered more than 18,000 research citations. He also holds numerous patents for his work in Oncology Drug Discovery.
Chief Financial Officer (Interim)
Mr. Karel is responsible for finance-related activities, including Biothera Pharmaceuticals’ accounting, financial planning and reporting, and strategic analysis. Previously he was Chief Financial Officer of Immuno Research Inc. (formerly Biothera Inc.) before becoming the Company’s Chief Operating Officer responsible for all research and technology development. He is now President and Chief Operating Officer for Immuno Research and a member of the Biothera Pharmaceuticals board of directors. Mr. Karel has a bachelor’s degree in Accounting from the University of St. Thomas and began his career as a CPA with KPMG LLP.